Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
暂无分享,去创建一个
I. Chirivella | R. Salazar | C. Conill | J. Maurel | A. Cervantes | M. Pera | R. Gallego | M. Martín-Richard | H. Manzano | X. Marfà
[1] M. Bains,et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Y. Doki,et al. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] V. Rusch,et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Judy L. Smith,et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Ginsberg,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Marinus,et al. MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.
[7] M. Meyers,et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.
[8] M. Talamini,et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Wang,et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.
[10] T. Kunkel,et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.
[11] P. Soulié,et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. , 1997, European journal of cancer.
[12] J. Bosset,et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. , 1997, The New England journal of medicine.
[13] S. Aebi,et al. The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.
[14] T. Walsh,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.
[15] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.
[16] D. Cain,et al. National cancer institute sponsored cooperative clinical trials , 1990, Cancer.
[17] Y. Robert,et al. [Correlation of diameters measured by x-ray computed tomography and intraparietal extension of squamous cell carcinoma of the thoracic esophagus. Apropos of 101 anatomoradiologic comparisons]. , 1990, Journal de chirurgie.
[18] C. S. Yang,et al. Research on esophageal cancer in China: a review. , 1980, Cancer research.